SENS-601

SENS-601 is an investigational adeno-associated virus (AAV)-based gene therapy being developed by Sensorion for the treatment of hereditary hearing loss caused by mutations in the GJB2 gene. The GJB2 gene encodes Connexin 26, a gap junction protein that is essential for maintaining potassium ion homeostasis in the cochlea, which is critical for the survival and function of hair cells. Mutations in GJB2 are the most common cause of congenital non-syndromic sensorineural hearing loss. SENS-601 is designed to deliver a functional copy of the GJB2 gene to the inner ear to restore Connexin 26 expression and potentially recover or preserve hearing. The program is part of a strategic collaboration with the Institut Pasteur and has received significant investment from Sanofi to support its advancement through preclinical development toward clinical trials.

Other names

GJB2 gene therapyGJB-2 gene therapyGJB 2 gene therapy